Biosense Technologiessp. z o.o.
Research and experimental development on biotechnology
Overview
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2020 – the filing deadline has passed. 1 of 2 financial statements was filed late (for 2019, 208 days late).
- 2020not filed
- 201911/05/2021
- 201810/07/2019
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2019.
Results vs industry
Industry
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board acting independently is authorized to submit declarations and sign on behalf of the company. In the case of a multi-member management board, two members of the management board acting jointly or one member of the management board together with a commercial proxy are authorized to submit declarations and sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 142 | $3,835.76 | 94.6667% | |
Others | 8 | $216.10 | 5.3333% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2019-03-19 to 2021-10-28.
Reason for removal: Art. 96 ust. 9a pkt 3 (VAT returns showing no transactions filed for 6 consecutive months or 2 quarters)
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Dec 6, 2024 | Dissolution without liquidation opened |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 9, 2019 | Aid for research and development projects: experimental development | $362.1K$362,134 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 9, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $101.2K$101,154 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 9, 2019 | Aid for research and development projects: industrial research | $93,680$93,680 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| VASA Therapeuticssp. z o.o. | $216,535.01 | vasatherapeutics.com | ||
| MultiqureS.A. | $149,394.35 | purebiologics.com | ||
| GenomtecS.A. | $54,746.36 | genomtec.com | ||
| Immbionicsp. z o.o. | $31,756.23 | immbionic.com.pl | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Medtransfersp. z o.o. | $21,666.01 | codete.com | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Centrum Transferu Technologii Meditransfer Iitdsp. z o.o. | $228.56 | iitd.pan.wroc.pl | ||
| Olenasp. z o.o. | – | imsolutions.pl |
Change history
| Date | Event | |
|---|---|---|
| 2018-06-18 | Share capital increase (10,000.00 PLN → 15,000.00 PLN) | |
| 2018-02-28 | Share capital increase (8,000.00 PLN → 10,000.00 PLN) | |
| 2017-11-08 | Entered in the register |
FAQ
Last updated: 2026-04-26